« Return to News | CROs/Service Providers

Clinquest Group Acquires Stake in Enceladus Pharmaceuticals

Monday, July 9, 2007 02:31 PM

Amsterdam-based CRO Clinquest Group has acquired a stake in Enceladus Pharmaceuticals, the Netherlands-based developer of the inflammatory disorder treatment Nanocort—the product is in phase II trials. Clinquest also gathered a group of additional investment groups to back Enceladus as it brings more products to market.

“The participation of Clinquest in our activities allows us to complete the phase IIa clinical proof-of-concept trial with Nanocort that is currently ongoing in The Netherlands. Therefore this means a major boost to our clinical development track,” said Bart Metselaar, founder and chief executive officer of Enceladus.

Clinquest said it believed in Enceladus’ development pipeline and in the future of Nanocort.

“By entering in this risk-sharing arrangement, we are able to support the further development of Nanocort and the entire liposomal development platform most efficiently,” said Cees Wortel, chief executive officer of Clinquest Group.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.